IMM-H007 (WS070117) is an orally active and potentAMPK(AMP-activated protein kinase) activator andTGFβ1(transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation ofAMPK. IMM-H007 negatively regulates endothelium inflammation through inactivatingNF-κBandJNK/AP1signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis^[1][2][3].

IMM-H007 inhibits fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulates fatty acid oxidation, autophagy, and export of hepatic lipids^[2].
IMM-H007 (200 mg/kg, Orally, once per day for 10 days) inhibits ISO-induced cardiac fibrosis and diastolic dysfunction independently of AMPKα2 expression, reduces ISO-induced Smad2/3 phosphorylation downstream of TGFβ1 and cardiac fibrosis via an AMPKα2-independent pathway, but the inhibition of TGFβ1 expression is AMPKα2-dependent^[3].

485.45

C₂₂H₂₃N₅O₈

1221412-23-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.